Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on Hemab Therapeutics, with five buy ratings and one hold rating. The average 12-month price target is $49.60, though recent targets range from $36 to $55.
• COAG opened at $51.74, near its 52-week high of $53.61, with a $2.42 billion market capitalization. The stock’s 50-day moving average is $37.46.
• Hemab reported a quarterly loss of $0.80 per share, missing the $0.63 consensus estimate, while insiders—including major shareholder RA Capital Management—purchased shares worth about $1.81 million over the last quarter.

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $49.60.

Several research firms have recently weighed in on COAG. Wall Street Zen raised shares of Hemab Therapeutics to a "hold" rating in a research report on Saturday, May 9th. The Goldman Sachs Group began coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a "buy" rating and a $36.00 price objective for the company. Evercore began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They set an "outperform" rating and a $50.00 price objective on the stock. Jefferies Financial Group boosted their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Finally, Wedbush restated an "outperform" rating and issued a $55.00 target price (up from $42.00) on shares of Hemab Therapeutics in a report on Monday, July 13th.

Hemab Therapeutics Price Performance

Shares of COAG opened at $51.74 on Wednesday. The business has a 50-day moving average of $37.46. The stock has a market cap of $2.42 billion and a PE ratio of -2.16. Hemab Therapeutics has a 1-year low of $23.00 and a 1-year high of $53.61.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.17). Equities analysts anticipate that Hemab Therapeutics will post -2.89 EPS for the current year.

Insiders Place Their Bets

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 61,523 shares of the company's stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the transaction, the insider owned 6,444,637 shares of the company's stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders acquired 72,467 shares of company stock worth $1,809,595 over the last quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source